AcquisitionJul 23, 2026Pending
🇺🇸 United States
NTNeuphoria Therapeutics Inc.SPScancell Holdings plc
Healthcare › Biotechnology
Deal valueUndisclosed
AnnouncedJul 23, 2026
ConsiderationStock
StructureOne-step merger
RegionNorth America
Cross-borderYes
Contingent paymentYes
Overview
Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. through a merger of an indirect, wholly-owned Scancell subsidiary into Neuphoria, with Neuphoria stockholders receiving Scancell ADSs based on an exchange ratio and one contingent value right per share.
Deal rationale
Scancell believes the merger, together with the PIPE Financing and UK Offerings, is the best option to obtain a Nasdaq listing and access additional capital to support the advancement of Scancell's pipeline and the operations of the combined company.
AI-generated from the SEC filingPendingHealthcare › BiotechnologyUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Stock |
Advisors
Buy-side
LPLeerink Partners
Sell-side
HCH.C. Wainwright & Co.
Parties
Target
NTNeuphoria Therapeutics Inc.
- Headquarters
- United States
- Ticker
- NEUP
Acquirer
SPScancell Holdings plc
- Headquarters
- United Kingdom
- Ticker
- —